FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis

Guselkumab, first approved for adults with plaque psoriasis in 2017, has now been approved for adults with active psoriatic arthritis (PsA). The FDA based its approval on two pivotal phase 3 trials.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news